BABA vs GAMB

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

The deterministic health profile is critically weak, highlighted by a Piotroski F-Score of 2/9 and a technical trend score of 0/100. While the company maintains impressive gross margins (90.78%) and strong revenue growth (31%), these are overshadowed by a severe collapse in earnings and a 70.6% one-year price decline. The stock is currently trading near its 52-week low, and despite a 'strong buy' analyst consensus, the recent quarterly earnings miss (-588.9% surprise) suggests a fundamental disconnect between analyst expectations and operational reality.